Follow Slashdot stories on Twitter

 



Forgot your password?
typodupeerror
×
Medicine

WHO Lists AstraZeneca/Oxford COVID-19 Vaccine for Emergency Use (yahoo.com) 65

The World Health Organization (WHO) on Monday listed AstraZeneca and Oxford University's COVID-19 vaccine for emergency use, widening access to the relatively inexpensive shot in the developing world. From a report: A WHO statement said it had approved the vaccine as produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India. "We now have all the pieces in place for the rapid distribution of vaccines. But we still need to scale up production," said Tedros Adhanom Ghebreyesus, WHO Director-General. The listing by the UN health agency comes days after a WHO panel provided interim recommendations on the vaccine, saying two doses with an interval of around 8 to 12 weeks must be given to all adults, and can be used in countries with the South African variant of the coronavirus as well. The AstraZeneca/Oxford shot has been hailed because it is cheaper and easier to distribute than some rivals, including Pfizer/BioNTech's, which was listed for emergency use by the WHO late in December.
This discussion has been archived. No new comments can be posted.

WHO Lists AstraZeneca/Oxford COVID-19 Vaccine for Emergency Use

Comments Filter:
  • by Anonymous Coward
    Also significantly less effective. [who.int] Basically a coin toss.
    • by dmay34 ( 6770232 ) on Monday February 15, 2021 @12:54PM (#61066070)

      It's less effective, but who cares? The FDA stated it would have approved any vaccine over 50%. A 50% reduction in infections would save many many lives.

      • by dbialac ( 320955 )
        Meanwhile a lot of states are choosing to defer vaccinating those at risk of death who aren't over 65, which will not save lives. There's also the potential problem with silent outbreaks happening in essential businesses such as grocery stores, risking their customers, since these vaccines are not proving to stop transmission. There are studies on the AZ vaccine, and I a friend of a friend caught it from somebody who was fully vaccinated in the US with one of the other vaccines.
      • It will also save lives if it reduces the impact of the virus on people who catch it
      • Even if it doesn't completely prevent infection, does it reduce the severity of infection in those remaining 50%?

      • That was way back when there were no vaccines at all. If 50% is best you can get then of course, by all means, some is better than nothing. But that's not the case anymore now is it. Rather it's AstraZeneca now, or something like Pfizer couple months later, that's a very different choice. Not only is AstraZeneca significantly less effective, there is at least one strain(South African) it has no effect on at all.
        I guess you can use it if you don't have anything better, but you can't treat it as if all vacc
    • by jeremyp ( 130771 )

      Well that depends on your definition of effectiveness. A vaccine that is 60% effective but that can be given to 100% of the people is better overall than a vaccine that is 100% effective but can only be given to 50% of the people.

      • It depends on whether it keeps you from getting a more effective vaccine later. A 50% effective vaccine now that prevents a 100% effective vaccine from being given in a few months may not be worth it.

    • About 20 years ago, I was flipping channels, and I ran across some stupid reality TV Show, I think families swapped wifes/mothers and they put some lady from a wealthy family in with a lower-middle class family.
      She was complaining because they were driving a car that was too small, not comfortable at all, and old and ran down, that needed some repairs. She was like just get a Mercedes SUV, that will fix all your problems. The Father of the family pointed out, that it was too expensive, and she responded i

    • by hey! ( 33014 )

      Not so much a coin toss as an occasion to weigh local circumstances. There are some places where the AstraZeneca vaccine is going to be a clear winner and other places where the mRNA vaccines would be clearly better.

    • It's less effective but not ineffective. People who have had the full dose are much less likely to get seriously ill or die from COVID and are less able to spread the disease, even if they catch it.

    • Third? I dunknow.

  • we are in a global pandemic

    • Pandemics have hot and cool zones. It isn't evenly distributed across all our global communities. Being that we do not have a unified government, and we don't pay Earth Taxes. Every country has unequal amount of tools help help fight it. So if a hot spot appears in a country with less resources, there is a real emergency, for them. Vs a larger country that may have resources to deal with such a hot spot.

  • by Anonymous Coward on Monday February 15, 2021 @12:56PM (#61066084)

    This is the one that made news in 2020 because they messed up the trials. That's all been memory holed now. Google for it and nothing comes up. The stories still exist though.

    https://www.nytimes.com/2020/1... [nytimes.com]
    https://www.wired.com/story/th... [wired.com]
    https://www.news18.com/news/in... [news18.com]

    • Another question I have been unable to find any useful answer too is how effective a booster shot will be. My original understanding of the adenovirus vector was that your body developed a level of immunity to the vector, which meant that subsequent attempts to use that vector would be ineffective (or at least, less effective). I know in previous trials with other vectors they have had problems with prior immunity within a community, but the counter to this is that a two shot regime of the vaccine seems to

      • by ceoyoyo ( 59147 )

        A booster shot might work okay. The second dose of the AZ vaccine, which is a booster after all, is the same viral vector. The immune system reacts to it, but usually not before it manages to infect some cells and get them to pump out spike protein.

        A well recognized problem with viral vector vaccines is that vaccines that use the same vector aren't likely to be effective, so you'd have to keep track of exactly which formulation of what you'd already gotten.

        Viral vector vaccines are probably going to get the

    • by tlhIngan ( 30335 )

      Huh? It googled just fine - I just googled for "astrazeneca trial 95 percent bad data" and it pops up all sorts of information about the bad trials that were run. I believe your NYT story was the first link as well.

      That's also why the approval is delayed so much - you have to remember that the trials and news were only announced around the october/november timeframe and was in competition with Moderna and Pfizer-BioNtech. But the bad data came about which forced them to have to restart all the trials and w

  • Not nearly as effective but I guess useful if you don't have any alternative available.
  • Uh.

    If you have a COVID emergency, it's already too late...

  • For a bit of perspective, let me report from a different world :). The vaccine Sputnik V is has been generally available since early December, and its clinical trials have recently been completed (showing it's basically on par with the other best vaccines). There are vaccination stations in many of the local hospitals, no queues, and they have a surplus of the vaccine sitting in the fridges and nurses waiting. There is no appointment needed, just come and get it. The problem: the population does not want to

  • If you're using a vaccine in an emergent situation, likely you're already screwed.

    It's not like *POKE* YOU ARE NOW IMMUNE!

    It takes time, days, sometimes weeks, for your body to begin producing the things it needs to fight off infection.

    • by Shimbo ( 100005 )

      If you're using a vaccine in an emergent situation, likely you're already screwed.

      The emergency is the pandemic; approvals have been fast tracked but are subject to later review.

  • I see lots of stories about them being shipped all over the place.... for free?

Most public domain software is free, at least at first glance.

Working...